Brand Name | Status | Last Update |
---|---|---|
abrilada | Biologic Licensing Application | 2024-01-26 |
adalimumab | Biologic Licensing Application | 2023-12-08 |
adalimumab-aacf | Biologic Licensing Application | 2023-12-02 |
adalimumab-adbm | Biologic Licensing Application | 2023-09-20 |
amjevita | Biologic Licensing Application | 2024-02-05 |
cyltezo | Biologic Licensing Application | 2023-07-12 |
hadlima | Biologic Licensing Application | 2023-10-23 |
hulio | Biologic Licensing Application | 2023-12-30 |
humira | Biologic Licensing Application | 2024-02-01 |
hyrimoz | Biologic Licensing Application | 2023-06-15 |
Expiration | Code | ||
---|---|---|---|
adalimumab, Cyltezo, Boehringer Ingelheim Pharmaceuticals, Inc. | |||
Date TBD | Interchangeable excl. | ||
adalimumab, Humira, AbbVie Inc. | |||
2028-02-24 | Orphan excl. |
Code | Description |
---|---|
J0135 | Injection, adalimumab, 20 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 4 | 26 | 57 | 64 | 91 | 239 |
Psoriasis | D011565 | EFO_0000676 | L40 | 3 | 10 | 34 | 21 | 47 | 111 |
Crohn disease | D003424 | EFO_0000384 | K50 | 3 | 8 | 31 | 22 | 51 | 110 |
Ulcerative colitis | D003093 | EFO_0000729 | K51 | 3 | 4 | 13 | 9 | 39 | 67 |
Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | 1 | 3 | 9 | 9 | 35 | 56 |
Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | 1 | 2 | 11 | 7 | 33 | 54 |
Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 2 | 3 | 2 | 7 | 21 | 33 |
Uveitis | D014605 | HP_0000554 | H20.9 | 1 | 7 | 8 | 3 | 4 | 21 |
Hidradenitis suppurativa | D017497 | — | L73.2 | 1 | 7 | 4 | 3 | 6 | 21 |
Spondylarthritis | D025241 | — | — | — | — | 1 | 6 | 5 | 12 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 24 | 1 | 1 | — | — | 25 |
Juvenile arthritis | D001171 | EFO_1002007 | M08 | — | 1 | 6 | — | 4 | 10 |
Pain | D010146 | EFO_0003843 | R52 | 1 | 1 | 1 | — | 2 | 4 |
Inflammation | D007249 | MP_0001845 | — | — | 1 | 1 | — | 2 | 4 |
Behcet syndrome | D001528 | EFO_0003780 | M35.2 | — | — | 2 | — | 2 | 4 |
Pyoderma gangrenosum | D017511 | EFO_0006835 | L88 | — | 2 | 1 | — | 1 | 4 |
Autoimmune diseases | D001327 | HP_0002960 | M30-M36 | 1 | 2 | 1 | — | — | 3 |
Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | 2 | 1 | — | — | 3 |
Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | — | 1 |
Pouchitis | D019449 | EFO_0003921 | K91.850 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 4 | — | — | — | 4 |
Focal segmental glomerulosclerosis | D005923 | EFO_0004236 | — | 1 | 2 | — | — | — | 3 |
Choroidal neovascularization | D020256 | — | — | 1 | 1 | — | — | — | 2 |
Mucopolysaccharidosis vi | D009087 | — | — | 2 | 2 | — | — | — | 2 |
Mucopolysaccharidosis i | D008059 | — | E76.0 | 2 | 2 | — | — | — | 2 |
Mucopolysaccharidosis ii | D016532 | — | E76.1 | 2 | 2 | — | — | — | 2 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | 1 | — | — | — | 1 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 1 | — | — | — | 1 |
Hypoglycemia | D007003 | HP_0001943 | E16.2 | 1 | 1 | — | — | — | 1 |
Hermanski-pudlak syndrome | D022861 | — | E70.331 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Uveal neoplasms | D014604 | EFO_1001230 | — | 1 | — | — | — | — | 1 |
Immune system diseases | D007154 | — | D89.9 | 1 | — | — | — | — | 1 |
Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Anaplastic thyroid carcinoma | D065646 | — | — | 1 | — | — | — | — | 1 |
Innate immunity | D007113 | — | — | 1 | — | — | — | — | 1 |
Diabetic retinopathy | D003930 | EFO_0003770 | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 2 | 2 |
Rheumatic diseases | D012216 | — | M79.0 | — | — | — | — | 2 | 2 |
Depression | D003863 | — | F33.9 | — | — | — | — | 2 | 2 |
Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | — | 2 | 2 |
Drug monitoring | D016903 | — | — | — | — | — | — | 2 | 2 |
Brain diseases | D001927 | HP_0001298 | G93.40 | — | — | — | — | 1 | 1 |
Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | — | 1 | 1 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 1 | 1 |
Dementia | D003704 | EFO_0003862 | F03 | — | — | — | — | 1 | 1 |
Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
Drug common name | Adalimumab |
INN | adalimumab |
Description | Adalimumab, sold under the brand name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. Use is generally only recommended in people who have not responded to other treatments. It is used by injection under the skin.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | >6CR1:H|Heavy chain of adalimumab EFab (VH-IgE CH2)
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLY
LQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPTVKILQSICDGGGHFPPTIQLLCLVSGYTPGTI
QITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTFEDSTKKCAHHHHHH
>6CR1:L|Light chain of adalimumab EFab (VL-IgE CH2)
DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQP
EDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTIQITWLEDGQVMDVD
LSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTFEDSGKKCA |
PDB | 3WD5, 4NYL, 6CR1 |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201580 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00051 |
UNII ID | FYS6T7F842 (ChemIDplus, GSRS) |